ThromboGenics NV, which is marketing a product for symptomatic vitreomacular adhesion, has appointed Joseph Markoff, an ophthalmic surgeon, as a scientific advisor to the company. Dr Markoff will report to the company’s chairman and work with medical affairs teams in the US and elsewhere. Dr Markoff founded a private eye care practice in the US and until recently was global director for scientific affairs in ophthalmology at Merck & Co. Inc.
ThromboGenics announced the appointment on 5 March 2015.
Copyright 2015 Evernow Publishing Ltd